NYSE:IQV - Iqvia Stock Price, Price Target & More

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) released its quarterly earnings data on Wednesday, May, 2nd. The medical research company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.27 by $0.07. The medical research company earned $2.56 billion during the quarter, compared to analyst estimates of $2.42 billion. Iqvia had a return on equity of 13.35% and a net margin of 13.07%. The business's revenue for the quarter was up 34.1% on a year-over-year basis. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Iqvia.

Iqvia issued an update on its FY18 earnings guidance on Friday, May, 18th. The company provided earnings per share (EPS) guidance of $5.20-5.45 for the period, compared to the Thomson Reuters consensus estimate of $5.40. The company issued revenue guidance of $10.05-10.25 billion, compared to the consensus revenue estimate of $10.15 billion.Iqvia also updated its Q2 guidance to $1.17-1.24 EPS.

17 equities research analysts have issued 1 year target prices for Iqvia's shares. Their forecasts range from $93.42 to $128.00. On average, they anticipate Iqvia's stock price to reach $110.3776 in the next twelve months. View Analyst Ratings for Iqvia.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).

Media headlines about IQV stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iqvia earned a daily sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the medical research company an impact score of 45.49 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Iqvia's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.63%), Farallon Capital Management LLC (1.52%), Northern Trust Corp (0.85%), Dimensional Fund Advisors LP (0.58%), Legal & General Group Plc (0.34%) and Schwab Charles Investment Management Inc. (0.28%). Company insiders that own Iqvia stock include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko and Robert Parks. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Sei Investments Co., Swiss National Bank, Guggenheim Capital LLC, The Manufacturers Life Insurance Company, Van ECK Associates Corp, Employees Retirement System of Texas and Northern Trust Corp. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, Kevin C Knightly, Michael J Evanisko and Robert Parks. View Insider Buying and Selling for Iqvia.

IQV stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Eagle Asset Management Inc., MD Sass Investors Services Inc., Carillon Tower Advisers Inc., Mackay Shields LLC, Farallon Capital Management LLC, Chilton Investment Co. LLC and Bloom Tree Partners LLC. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $103.84.

Iqvia has a market capitalization of $21.61 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. Iqvia employs 55,000 workers across the globe.

Iqvia's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 203-448-4600 or via email at [email protected]